Alibrex
Pre-commercial- Indications
- Stage IV colorectal cancer, Stage IV breast cancer, Stage IV lung cancer
Company intelligence / Profile preview
Cadex Genomics has developed Alibrex, a blood-based liquid biopsy assay that uses retrotransposon-targeted qPCR to monitor real-time therapy response in patients with stage IV solid tumors. The technology enables oncologists to assess treatment effectiveness within weeks, potentially allowing earlier adjustments to care compared to standard imaging or mutation-matching ctDNA tests. Clinical results indicate the platform can deliver actionable information within 48 hours after specimen collection, improving timeliness and cost-effectiveness over existing methods. No published large-scale clinical trial data found.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cadex Genomics.